About Immunai
Immunai is an AI-powered biotechnology platform that maps and analyzes the human immune system to improve drug discovery and clinical trials. It uses advanced machine learning and single-cell biology to understand how immune cells behave in different diseases and how patients respond to treatments. The goal is to make drug development faster, more accurate, and more personalized, especially in areas like cancer and autoimmune diseases.
Feature Highlights
Immunai builds a large immune system database called AMICA, which contains massive single-cell biological data from patients across many diseases and clinical studies.
It uses AI and machine learning models to predict how the immune system will react to different drugs and treatments.
The platform helps identify which patients will respond or not respond to a treatment, improving clinical trial success rates.
It supports biomarker discovery, helping researchers find biological signals linked to disease and treatment response.
It integrates multi-omics data (genes, proteins, immune cell behavior) for deep biological analysis.
It works closely with pharmaceutical companies to improve drug development and reduce trial failure risk.
Use Cases
Improving clinical trials by selecting better patient groups
Helping pharmaceutical companies develop new drugs faster
Studying cancer and autoimmune disease immune responses
Finding biomarkers that predict treatment success
Reducing drug development cost and failure risk
Supporting precision medicine research
Building full digital immune system maps for global research
Using AI to predict disease progression before symptoms appear
Combining multiple disease datasets to discover cross-disease immune patterns